If you searched this phrase, you have probably already scrolled past a dozen clinic pages with paired photos and a caption about “12 weeks later.” That is not what this page gives you. Here is the honest reason why: nobody has ever run a trial that measured what sermorelin does to how a person looks. Not one. What exists is a small amount of real physiological data, one meaningfully positive trial, and a lot of marketing built on top of a thin evidentiary base.
For the full trial-by-trial read on whether this drug works at all, see does sermorelin work. This page focuses narrowly on the “before and after” question: what changed, for whom, and over what timeframe.
What sermorelin actually changes, mechanically
Sermorelin is not growth hormone. It is a fragment of growth-hormone-releasing hormone — the signal your hypothalamus already sends to your pituitary gland to release your own GH. Injecting sermorelin nightly prompts a pulse of your own GH release rather than adding synthetic GH directly [1]. In an eight-child pediatric trial using continuous infusion for up to a year, that pulsatile stimulation kept working. The pituitary did not wear out or go numb to the signal — researchers described “sustained augmentation of pulsatile GH secretion without evidence of desensitization” [2]. That is a genuinely interesting mechanism. It is also a separate question from whether it changes anything a buyer would notice.
The one trial that matters
There is exactly one placebo-controlled trial that gave sermorelin to non-GH-deficient adults and measured real-world outcomes rather than just a blood marker. It is Khorram and colleagues, 1997: 19 people (10 women, 9 men, ages 55–71), five months, nightly injections [1]. That is the whole adult evidence base for “before and after.”
Quoted directly from the results: “GHRH analog treatment resulted in a significant increase in skin thickness (P < 0.05) in both genders and increased lean body mass in men only (P < 0.05), with no other changes in body composition or bone mineral density in either gender” [1]. On quality-of-life measures: “a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women, and sleep quality was unaffected in both genders” [1].
What actually moved
- Lean body mass rose in the men in the study — a real, measured outcome, not just a lab value.
- Skin thickness increased in both men and women.
- GH and IGF-1 rose substantially — a companion paper on the same cohort reported GH increases up to 107% and IGF-1 increases up to 28% [3].
- Well-being and libido improved, but only in the men.
What did not move at all
- Sleep quality — unaffected in both sexes, despite better sleep being one of the most common things sermorelin is marketed for.
- Bone mineral density — no change in either sex.
- Any body-composition or quality-of-life measure in women — the trial found essentially nothing for half its participants. That is why our board for women leads with this gap rather than with a seller.
That split matters. A trial that shows benefit in men and nothing in women is not a trial you can round up to “sermorelin works.” It is a trial that found a specific, modest, sex-limited effect. That is still the most rigorous data anyone has.
Why there is not a second trial to check this against
Sermorelin has been studied since the 1980s. But a search of everything PubMed has ever indexed on the drug turns up only ten randomized controlled trials total, across every age group and use case [1][4][5]. The Khorram result — the only positive adult outcome trial — has never been replicated. Not refuted, not confirmed. Just left alone for 29 years while an entire commercial industry grew up around it.
Why you will not see transformation photos on this site
Every claim above comes from body-composition scans, lab draws, and validated quality-of-life questionnaires — not photographs. No published trial has ever measured or reported visual, photographic change from sermorelin, in any population. A before-and-after photo pair implies a measured, attributable, visual outcome that the research does not contain. Any photos on a seller’s page are showing you something the trials never tested. That is typically over a period where diet, training, sleep, and simple lighting differences can outweigh anything a GHRH peptide might contribute.
What you can realistically expect to track
If you want to know whether sermorelin is doing anything for you, track things that were actually measured in the literature. Use a timeframe that matches the trial:
- IGF-1 on a lab panel. The most direct, trial-supported biomarker — the Khorram cohort’s IGF-1 and GH levels rose within two weeks of starting treatment [1][3]. It tells you the mechanism is engaging, not that any downstream benefit will follow.
- A body-composition scan (not a scale, not a photo). The only real body-composition change ever documented was lean mass in men, over roughly four to five months of nightly use.
- A subjective log of energy, libido, and general well-being — this is what actually improved in the male trial participants. The source trial found nothing comparable in women.
- Sleep, only to confirm the trial’s own finding: do not expect this to be the thing that changes.
Pediatric growth-hormone-deficiency trials add one more useful data point on timing. In a head-to-head comparison against actual GH in GH-deficient children, real GH produced meaningfully faster growth than the GHRH analog at either of two doses tested. Doubling the GHRH dose did not close the gap [4]. See sermorelin vs. HGH for the full comparison. It is a different population and a different outcome, but a useful reminder that GHRH analogs are not simply a slower version of GH.
What happens after you stop
This is a question almost nobody asks before they start, and the honest answer is that it is barely been studied in adults at all. The only controlled data on stopping sermorelin comes from a pediatric growth trial: in the eight-child continuous-infusion study, “a return to pretreatment growth rates was seen after cessation of treatment in all children” [2]. Growth velocity, not lean mass or energy, and children, not adults — but it is the only measured discontinuation finding that exists for this drug. For the outcomes adults actually care about, there is no published follow-up at all. See what the studies actually dosed for how that gap compounds with the dosing question.
The bottom line
The honest “before and after” story for sermorelin is short. In the one real adult trial that exists, men who took it nightly for about five months gained measurable lean mass and reported better well-being and libido. Women in the same trial saw essentially nothing outside of skin thickness. Nobody’s sleep changed. And nobody has repeated the study since 1997. That is not a story that photographs well, which is probably part of why it does not get told this plainly very often. As far as the published record goes, it is the truth. If you are choosing a seller rather than deciding whether to start, the injection board has the pricing.